CG Oncology Q2 Loss Widens to $79M, Cash Drops to $1B as R&D Costs Surge
CGON has more than doubled off its 52-week low of $23.65.
Summary
CG Oncology's Q2 net loss widened to $79.1 million from $60.2 million in Q1, driven by higher clinical trial and compensation costs. Revenue reached $1.2 million, reflecting early commercialization. Cash declined to $1.0 billion from $1.076 billion, still funding operations through 2029. The company expects near-term PIVOT-006 Phase 3 data and a BLA submission in Q4 2026 for its bladder cancer therapy. The accelerating cash burn and upcoming binary catalysts make this a critical juncture for the stock.
At the time of this announcement, CGON was trading at $71.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $23.65 to $77.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.